These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 24375514

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H, Youk J, Kim I, Yoon SS, Park S, Lee JO, Bang SM, Koh Y.
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ye P, Pei R, Jin J, Sun J, Li K, Cao J, Zhou D, Lu Y.
    Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
    Paubelle E, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Plesa A, Salles G, Wattel E, Thomas X.
    Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W, Mao L, Qian J, Qian W, Meng H, Mai W, Tong H, Tong Y, Jin J.
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [Abstract] [Full Text] [Related]

  • 14. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
    Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H.
    Blood; 2010 Dec 23; 116(26):5818-23; quiz 6153. PubMed ID: 20923968
    [Abstract] [Full Text] [Related]

  • 15. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.
    Cancer; 2018 Jun 15; 124(12):2534-2540. PubMed ID: 29645075
    [Abstract] [Full Text] [Related]

  • 16. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
    Gill H, Yim R, Pang HH, Lee P, Chan TSY, Hwang YY, Leung GMK, Ip HW, Leung RYY, Yip SF, Kho B, Lee HKK, Mak V, Chan CC, Lau JSM, Lau CK, Lin SY, Wong RSM, Li W, Ma ESK, Li J, Panagiotou G, Sim JPY, Lie AKW, Kwong YL.
    Cancer Med; 2020 May 15; 9(10):3371-3382. PubMed ID: 32187883
    [Abstract] [Full Text] [Related]

  • 17. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
    Tang W, Fan X, Wang L, Hu J.
    Medicine (Baltimore); 2015 Apr 15; 94(15):e706. PubMed ID: 25881847
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
    Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.
    Leuk Res; 2015 Sep 15; 39(9):945-9. PubMed ID: 26154683
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.